Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Pre-operative Carbohydrate Loading Patients With Diabetes Undergoing Elective Colorectal Surgery
Goal to evaluate the feasibility of conducting a large study that would assess the safety of
carbohydrate drinks (i.e. juice) prior to elective colorectal surgery in patients with type 2
diabetes.
Traditionally, prior to surgeries involving general anesthetic, patients have been told not
to eat or drink anything after midnight due to the risk of aspiration. More recent research
have shown that it is safe to have clear fluids up to 2 hours before an operation and this is
reflected in the current anesthesia clinical guidelines.
It is currently not known if it is safe for patients with type 2 diabetes to have a sugar
drink before their surgery since they have trouble processing sugars and a subset of patients
with diabetes are at increased risk to aspiration due to delayed gastric emptying.
Fasting prior to the administration of a general anesthetic has been the standard of
peri-operative care for many years. The refrain of "nothing to eat or drink after midnight"
has become synonymous with surgery for both clinicians and the general public. The rationale
behind this practice has been to reduce the risk of regurgitation of gastric contents. In
addition, this instruction is straightforward for patients and ancillary staff, and allows
for easy alteration of the order of cases on the operative list. Despite the widespread
nature of this practice, a 2003 Cochrane review attempted to define the optimum duration of
fasting, type of fasting, and volume of intake permitted and concluded that there was no
evidence to suggest a shortened fluid fast resulted in an increased risk of aspiration,
regurgitation, or morbidity in healthy patients.
Pre-operative fasting leads to insulin resistance and metabolic stresses. More recently it
has been suggested that a preoperative carbohydrate loading may alleviate some deleterious
effects of this fast. This strategy, combined with a number of others, have been recently
introduced in many Enhanced Recovery After Surgery (ERAS) programs, that have led to improved
postoperative pain, faster restoration of GI function, decreased LOS and decreased
complication rate after colon surgery.
Type 2 diabetes is a disease of impaired glucose tolerance. It is a common condition that
affects over 15% of general surgical patients undergoing major abdominal surgery. It is well
recognized that this is a high-risk surgical population that is at increased risk of
perioperative complications such as anastomotic dehiscence, poor wound healing, and
postoperative ileus which can lead to an increased LOS after surgery. However, there is a
relative dearth of robust evidence regarding preoperative fasting in patients with type 2
diabetes so there is no consensus among professional association guidelines internationally
on recommendations for carbohydrate loading in this population undergoing elective surgery.
Two major concerns have been raised; first the risk of aspiration in diabetic patients with a
significant neuropathy and gastroparesis, and second potential for hyperglycemia and its
deleterious effects.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |